References

nogr

Экспериментальная и клиническая гастроэнтерология

Experimental and Clinical Gastroenterology

1682-8658

«Global Media Technologies»

10.31146/1682-8658-ecg-218-10-153-159

nogr-2559

Research Article

ГЕПАТОЛОГИЯ

HEPATOLOGY

Матриксные металлопротеиназы и морфологическая картина при хронических заболеваниях печени

Matrix metalloproteinases and morphological features in chronic liver diseases

https://orcid.org/0000-0002-5727-1640

Ягода

А. В.

Yagoda

A. V.

noemail@neicon.ru

https://orcid.org/0000-0001-6392-8461

Корой

П. В.

Koroy

P. V.

noemail@neicon.ru

https://orcid.org/0009-0006-7244-3507

Дудов

Т. Р.

Dudov

T. R.

timur222123@mail.ru

Федеральное государственное бюджетное образовательное учреждение высшего образования «Ставропольский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияStavropol State Medical UniversityRussian Federation

2023

15032024

010153159

2024

Ягода А.В., Корой П.В., Дудов Т.Р.

Yagoda A.V., Koroy P.V., Dudov T.R.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.nogr.org/jour/article/view/2559

Цель исследования. Изучить взаимосвязь матриксных металлопротеиназ (ММП) и их тканевых ингибиторов (ТИМП) с морфологической картиной хронических заболеваний печени (ХЗП). Материалы и методы. Обследовано 76 больных ХЗП вирусной или алкогольной этиологии в возрасте от 18 до 64 лет. Хронический гепатит диагностирован у 59 пациентов, цирроз печени класса А по Child-Pugh выявлен в 17 случаях. Группу контроля составили 72 практически здоровых человека. Методом иммуноферментного анализа определяли содержание в крови ММП-1, ММП-9, ТИМП-1, рассчитывали соотношение ТИМП-1/ММП-1, ТИМП-1/ММП-9. Результаты. При ХЗП наблюдалось увеличение концентрации ТИМП-1 и ММП-1 в крови, соотношения ТИМП-1/ММП-9, снижение коэффициента ТИМП-1/ММП-1. При умеренной и высокой гистологической активности ХЗП показатели ТИМП-1, ММП-9 были выше, а соотношение ТИМП-1/ММП-9 - ниже, чем у пациентов со значениями индекса гистологической активности менее 9 баллов. У больных циррозом печени (фиброз F4) определялись максимальные величины ТИМП-1, ТИМП-1/ММП-1 и ТИМП-1/ММП-9, которые отличались от соответствующих значений при фиброзе F0-1 и F2. Уровни ММП-9 в крови более 410 нг/мл прогнозировали выраженное воспаление при ХЗП с точностью 82,9%. Показатели ТИМП-1 выше 624 нг/мл, ТИМП-1/ММП-1 более 37,1 у. е., ТИМП-1/ММП-9 более 7,33 у. е. имели высокую точность (82,9, 80,3, 80,3% соответственно) в предикции цирроза печени (фиброза F4). Заключение. Дисбаланс в системе матриксных металлопротеиназ связан с морфологической картиной ХЗП и характеризуется гиперэкспрессией ММП-9 в случаях выраженного воспаления и повышенной активностью ТИМП-1 при тяжелых стадиях фиброза печени.

Aim of investigation. To study the relationship of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) with a morphological features of chronic liver diseases (CLD). Materials and methods. 76 patients with CLD of viral or alcoholic etiology aged from 18 to 64 years were examined. Chronic hepatitis was diagnosed in 59 patients, liver cirrhosis (class A according Child-Pugh score) was detected in 17 cases. The control group consisted of 72 practically healthy people. The blood levels of MMP-1, MMP-9, TIMP-1 were determined by enzyme immunoassay, and the ratio of TIMP-1/MMP-1, TIMP-1/MMP-9 was calculated. Results. There was an increase in the concentration of TIMP-1 and MMP-1 in the blood, the ratio of TIMP-1/MMP-9, a decrease in the ratio of TIMP-1/MMP-1 in CLD. In moderate and severe histological activity of CLD the levels of TIMP-1 and MMP-9 were higher, and the ratio of TIMP-1/MMP-9 was lower than in patients with histological activity index values less than 9 points. In patients with liver cirrhosis (fibrosis F4), the maximum values of TIMP-1, TIMP-1/MMP-1 and TIMP-1/MMP-9 were determined, which differed from the corresponding values for fibrosis F0-1 and F2. The blood levels of MMP-9 more than 410 ng/ml predicted severe inflammation in CLD with an accuracy of 82.9 %. The blood levels of TIMP-1 above 624 ng/ml, TIMP-1/MMP-1 more than 37.1, TIMP-1/MMP-9 more than 7.33 had high accuracy (82.9, 80.3, 80.3 %, respectively) in the prediction of liver cirrhosis (fibrosis F4). Conclusion. The imbalance in the matrix metalloproteinase system is associated with the morphological features of CLD and is characterized by hyperexpression of MMP-9 in cases of severe inflammation and increased activity of TIMP-1 in severe stages of liver fibrosis.

хронические заболевания печениматриксные металлопротеиназытканевые ингибиторы матриксных металлопротеиназгистологическая активностьфиброз печени

chronic liver diseasesmatrix metalloproteinasestissue inhibitors of matrix metalloproteinaseshistological activityliver fibrosis

References1

Cheemerla S., Balakrishnan M. Global epidemiology of chronic liver disease. Clin. Liver Dis. 2021; 17 (5): 365-370. doi: 10.1002/cld.1061.

Duarte S., Baber J., Fujii T., Coito A. J. Matrix metalloproteinases in liver injury, repair and fibrosis. Matrix Biol. 2015; 44-46: 147-156. doi: 10.1016/j.matbio.2015.01.004.

Geervliet E., Bansal R. Matrix metalloproteinases as potential biomarkers and therapeutic targets in liver diseases. Cells. 2020; 9: 1212. doi: 10.3390/cells9051212.

Foglia B., Cannito S., Bocca C. et al. ERK pathway in activated, myofibroblast-like, hepatic stellate cells: a critical signaling crossroad sustaining liver fibrosis.Int. J. Mol. Sci. 2019; 20 (11): 2700. doi: 10.3390/ijms20112700.

Roeb E. Matrix metalloproteinases and liver fibrosis (translational aspects). Matrix Biol. 2018; 68-69: 463-473. doi: 10.1016/j.matbio.2017.12.012.

Naim A., Pan Q., Baig M. S. Matrix metalloproteinases (MMPs) in liver diseases. J. Clin. Exp. Hepatol. 2017; 7: 367-372. doi: 10.1016/j.jceh.2017.09.004.

Thiele N. D., Wirth J. W., Steins D. et al. TIMP-1 is upregulated, but not essential in hepatic fibrogenesis and carcinogenesis in mice. Sci. Rep. 2017; 7: 714. doi: 10.1038/s41598-017-00671-1.

Kerola A., Lampela H., Lohi J. et al. Increased MMP-7 expression in biliary epithelium and serum underpins native liver fibrosis after successful portoenterostomy in biliary atresia. J. Path. Clin. Res. 2016; 2: 187-198. doi: 10.1002/cjp2.50.

Lam S., Singh R., Dillman J. R. et al. Serum matrix metalloproteinase 7 is a diagnostic biomarker of biliary injury and fibrosis in pediatric autoimmune liver disease. Hepatology Communications. 2020; 4 (11): 1680-1693. doi: 10.1002/hep4.1589.

Behairy O. G., El-Bakry M. M., Mansour A. I. et al. Matrix metalloproteinase-1 as a non-invasive biomarker to assess liver fibrosis in children with chronic liver disease. Egypt. Liver J. 2021; 11: 80. doi: 10.1186/s43066-021-00148-x.

Irvine K. M., Wockner L. F., Hoffmann I. et al. Multiplex serum protein analysis identifies novel biomarkers of advanced fibrosis in patients with chronic liver disease with the potential to improve diagnostic accuracy of established biomarkers. PLoS One. 2016; 11 (11): e0167001. doi: 10.1371/journal.pone.0167001.

Ando W., Yokomori H., Tsutsui N. et al. Serum matrix metalloproteinase-1 level represents disease activity as opposed to fibrosis in patients with histologically proven nonalcoholic steatohepatitis. Clin. Mol. Hepatol. 2018; 24 (1): 61-76. doi: 10.3350/cmh.2017.0030.

Irvine K. M., Okano S., Patel P. J. et al. Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease. Sci. Rep. 2021; 11 (1): 2858. doi: 10.1038/s41598-021-82315-z.

Martinez-Castillo M., Hernandez-Barragan A., Flores-Vasconcelos I. et al. Production and activity of matrix metalloproteinases during liver fibrosis progression of chronic hepatitis C patients. World J. Hepatol. 2021; 13 (2): 218-232. doi: 10.4254/wjh.v13.i2.218.

Medeiros T., Saraiva G. N., Moraes L. A. et al. Liver fibrosis improvement in chronic hepatitis C after direct acting-antivirals is accompanied by reduced profibrogenic biomarkers-a role for MMP-9/TIMP-1. Dig. Liver Dis. 2020; 52 (10): 1170-1177. doi: 10.1016/j.dld.2020.05.004.

Attallah A. M., Albannan M. S., El-Deen M. S. et al. Diagnostic role of collagen-III and matrix metalloproteinase-1 for early detection of hepatocellular carcinoma. Br. J. Biomed. Sci. 2020; 77 (2): 58-63. doi: 10.1080/09674845.2019.1708534.

Lertudomphonwanit C., Mourya R., Fei L. et al. Large-scale proteomics identifies MMP-7 as a sentinel of epithelial injury and of biliary atresia. Sci. Transl. Med. 2017; 9 (417): eaan8462. doi: 10.1126/scitranslmed.aan8462.

Pérez-Is L., Collazos J., Fuente B. et al. 24-month decline of non-invasive liver fibrosis markers in HCV-mono and HCV/HIV coinfection after direct-acting antiviral therapy. Sci. Rep. 2022; 12: 3828. doi: 10.1038/s41598-022-07548-y.

Koroy P. V., Dudov T. R., Yagoda A. V. Matrix metalloproteinases system in chronic liver diseases. Medical News of North Caucasus. 2023; 18 (3): 251-256. (In Russ.) doi: 10.14300/mnnc.2023.18059.@@ Корой П. В., Дудов Т. Р., Ягода А. В. Система матриксных металлопротеиназ при хронической патологии печени. Медицинский вестник Северного Кавказа. 2023; 18 (3): 251-256. doi: 10.14300/mnnc.2023.18059.

Roderfeld M. Matrix metalloproteinase functions in hepatic injury and fibrosis. Matrix Biol. 2018; 68-69: 452-462. doi: 10.1016/j.matbio.2017.11.011.

Wang X., Maretti-Mira A. C., Wang L., Deleve L. D. Liver-selective MMP-9 inhibition in the rat eliminates ischemia-reperfusion injury and accelerates liver regeneration. Hepatology. 2019; 69: 314-328. doi: 10.1002/hep.30169

Yu D., Li Y., Xu Y. et al. Dysregulated matrix metalloproteinases and tissue inhibitors of metalloproteinase in residual splenic tissue after subtotal splenectomy due to portal hypertension.Int. J. Clin. Exp. Pathol. 2017; 10 (2): 1273-1282.

Jones T. K., Reilly J. P., Anderson B. J. et al. Elevated plasma levels of matrix metalloproteinase-3 and tissue-inhibitor of matrix metalloproteinases-1 associate with organ dysfunction and mortality in sepsis. Shock. 2022; 57 (1): 41-47. doi: 10.1097/SHK.0000000000001833.

Serrano-Gomez S., Burgos-Angulo G., Nino-Vargas D. C. et al. Predictive value of matrix metalloproteinases and their inhibitors for mortality in septic patients: a cohort study. J.Intensive Care Medicine. 2020; 35 (1): 95-103. doi: 10.1177/0885066617732284.

Sufleţel R. T., Melincovici C. S., Gheban B. A. et al. Hepatic stellate cells - from past till present: morphology, human markers, human cell lines, behavior in normal and liver pathology. Rom. J. Morphol. Embryol. 2020; 61 (3): 615-642. doi: 10.47162/RJME.61.3.01.

Metwally K., Fouad T., Shible N. et al. Metalloproteinase inhibitor-1 closely correlates with the severity of liver disease in Egyptian patients. J. Liver Disease Transplant. 2017; 6 (4): 1000157. doi: 10.4172/2325-9612.1000157

Yilmaz Y., Eren F. Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology. Eur. J. Gastroenterol. Hepatol. 2019; 31 (1): 43-46. doi: 10.1097/MEG.0000000000001240.

Wu J.-F., Jeng Y.-M., Chen H.-L. et al. Quantification of serum matrix metallopeptide 7 levels may assist in the diagnosis and predict the outcome for patients with biliary atresia. J. Pediatr. 2019; 208: 30-37. doi: 10.1016/j.jpeds.2018.12.006.

Collazos J., Valle-Garay E., Suárez-Zarracina T. et al. Matrix metalloproteases and their tissue inhibitors in non-alcoholic liver fibrosis of human immunodeficiency virusinfected patients. World J. Virol. 2017; 6 (2): 36-45. http://dx.doi.org/10.5501/wjv.v6.i2.36.

Guesiry D. E., Moez P., Hossam N., Kassem M. Usefulness of non-invasive serum markers for predicting liver fibrosis in Egyptian patients with chronic HCV infection. Egypt. J. Immunol. 2011; 18 (2): 1-12.

Liang B., Li Y., Zhao A. et al. Clinical utility of serum matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 concentrations in the assessment of liver fibrosis due to chronic hepatitis B. J.Int. Med. Res. 2012; 40 (2): 631-639. doi: 10.1177/147323001204000225.

Attallah A. M., Badr El-Din N. K., Omran M. M. et al. Assessment of matrix metalloproteinase-1 for marking liver cirrhosis in chronic hepatitis C patients. Egypt. J. Immunol. 2011; 18 (1): 33-42.

Attallah A. M., El-Far M., Malak C. A. A. et al. Fibro-check: a combination of direct and indirect markers for liver fibrosis staging in chronic hepatitis C patients. Annals of Hepatology. 2015; 14 (2): 225-233.

Latronico T., Mascia C., Pati I. et al. Liver fibrosis in HCV monoinfected and HIV/HCV coinfected patients: dysregulation of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) and effect of HCV protease inhibitors.Int. J. Mol. Sci. 2016; 17: 455. doi: 10.3390/ijms17040455.

The authors declare that there are no conflicts of interest present.